Study on Proton Radiotherapy of Thymic Malignancies

Launched by ASS. PROF. JAN NYMAN · Mar 25, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the use of proton beam radiotherapy for patients with thymic malignancies, specifically thymoma and thymic carcinoma. This treatment is being studied in patients who have had surgery for their cancer or those whose tumors cannot be surgically removed but are still localized. The main goals of the study are to understand how safe the treatment is—especially concerning heart and lung health—and to see how well it helps control the cancer over a five-year period.

To be eligible for this trial, participants should be at least 18 years old and have a confirmed diagnosis of thymic cancer. They should also meet certain health criteria, such as having a good performance status and adequate lung function. Individuals with advanced cancer that has spread, those who are pregnant, or those with serious health issues that could interfere with the study cannot participate. Participants can expect to receive proton therapy and will be monitored for their health and quality of life throughout the trial. This study is currently recruiting participants, and your involvement could contribute to important findings in the treatment of thymic cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological or cytological diagnosis of thymoma or thymic carcinoma.
• • With radical surgery: stage III and IVa and selected stage II with type B2, B3 and thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or inoperable patient/ patient refusing surgery: stage I - IVa, any histology
• • PS WHO 0 - 2.
• • FEV1 \> 1L or \>40 % of predicted and CO diffusion capacity \> 40% of predicted (postoperative measures)
• • Age \>18 years, no upper age limit.
• • Written informed consent from patients.
• Exclusion Criteria:
• • Masaoka-Koga stage IVb (distant metastases).
• • Pregnancy.
• • Serious concomitant systemic disorder incompatible with the study.
• • Tumour motion \> 0.5 cm on two repeated 4DCT